Dyadic International (DYAI) Net Income towards Common Stockholders Growth (1y) (2019 - 2026)
Powered by 
Analysis
Dyadic International (DYAI) Net Income towards Common Stockholders Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 65.85% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -635.24% |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 6.48% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | -6.81% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 92.37% |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | 5.21% |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 327.74% |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | -84.64% |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 18.24 Mn | 10.27 Mn | - | 4.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 4.66% |
| Dec 31, 2025 | -0.33% |
| Sep 30, 2025 | -1,086.87% |
| Jun 30, 2025 | 11.21% |
| Mar 31, 2025 | 2.74% |
| Dec 31, 2024 | 26.86% |
| Sep 30, 2024 | 89.83% |
| Jun 30, 2024 | 8.64% |
| Mar 31, 2024 | -5.86% |
| Dec 31, 2023 | 3.48% |
| Sep 30, 2023 | 10.77% |
| Jun 30, 2023 | 33.66% |
| Mar 31, 2023 | 29.03% |
| Dec 31, 2022 | 49.06% |
| Sep 30, 2022 | 45.52% |
| Jun 30, 2022 | 14.51% |
| Mar 31, 2022 | 99.92% |
| Dec 31, 2021 | -114.97% |
| Sep 30, 2021 | -32.86% |
| Jun 30, 2021 | -45.06% |